Loading...
Printed on 7/19/2026
For informational purposes only. This is not medical advice.
The simplified Pulmonary Embolism Severity Index (sPESI) is a validated 6-variable risk tool for adults with confirmed pulmonary embolism. It classifies patients into low risk (score 0) versus higher risk (score 1 or more) for short-term mortality. It is commonly used to support decisions around outpatient management versus inpatient monitoring.
Formula: sPESI = 1 point each for: age >80, cancer history, chronic cardiopulmonary disease, HR ≥110, SBP <100, SpO2 <90.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
After pulmonary embolism is confirmed (by CT-PA or V/Q scan), score each of the 6 sPESI variables: age >80 years, active cancer, chronic cardiopulmonary disease (heart failure, COPD, or chronic lung disease), heart rate ≥110 bpm, systolic BP <100 mmHg, and SpO2 <90%. Each item present scores 1 point.
Add up the applicable points. The total sPESI score ranges from 0 to 6. Most patients will score in the 0–3 range. A score of 0 places the patient in the low-risk category; any score of 1 or more places the patient in the high-risk category for 30-day adverse outcomes.
sPESI 0 = low risk (30-day mortality ~1.1%) — consider eligibility for outpatient treatment if also troponin-negative and RV function normal. sPESI ≥1 = high risk (30-day mortality ~8.9%) — inpatient treatment required; obtain echocardiography to assess RV function; measure troponin and BNP to further classify intermediate vs high risk.
Emergency physicians, hospitalists, pulmonologists
sPESI is calculated immediately after PE diagnosis to classify patients into low-risk (sPESI 0) versus higher-risk (sPESI ≥1) categories. This guides the subsequent workup — whether to obtain echocardiography, troponin, or BNP — and determines appropriate care level (outpatient vs inpatient).
Emergency physicians, anticoagulation clinics
sPESI 0 is a prerequisite for outpatient PE treatment consideration. Combined with negative troponin, absence of RV dysfunction on CT-PA or echo, no Hestia exclusion criteria, and access to reliable follow-up, sPESI 0 patients may be safely discharged with oral anticoagulation (rivaroxaban or apixaban).
Emergency physicians, cardiologists
sPESI ≥1 identifies patients who require echocardiography to assess right ventricular (RV) function. RV dysfunction combined with elevated troponin (intermediate-high risk PE) may warrant escalation to catheter-directed thrombolysis or PERT consultation.
Hospitalists, intensivists, emergency medicine
sPESI combined with hemodynamic stability and biomarker data guides care-level decisions: sPESI 0 + stable + negative biomarkers = potential outpatient; sPESI ≥1 + stable + positive troponin = intermediate risk, admit to monitored ward; sPESI ≥1 + hemodynamically unstable = high risk, consider ICU and thrombolysis.
Clinical researchers, trialists
sPESI is used as a stratification variable in major PE clinical trials to ensure balanced allocation between treatment arms. The binary low-risk/high-risk classification enables straightforward subgroup analysis.
sPESI 0 is a necessary but not sufficient criterion for outpatient PE management. ESC 2019 Guidelines require: sPESI 0 + negative troponin + absence of RV dysfunction on imaging (CT-PA RV/LV ratio <1.0 or normal echo). Social factors (adequate home support, medication access, reliable follow-up within 48–72h) are also essential.
Any sPESI ≥1 places the patient in the intermediate risk category at minimum. The next step is echocardiography (or CT-PA RV assessment) and troponin measurement. Intermediate-high risk PE (sPESI ≥1 + RV dysfunction + elevated troponin) may benefit from catheter-directed thrombolysis.
Hemodynamically unstable PE (persistent SBP <90 mmHg or >40 mmHg drop, or shock) is classified as high-risk (massive) PE. These patients require thrombolysis consideration or surgical/catheter embolectomy regardless of sPESI score. Do not apply sPESI-based outpatient criteria to unstable patients.
Systemic thrombolysis (alteplase 100 mg over 2h) for confirmed massive PE results in rapid hemodynamic improvement (60–80% response rate) but carries hemorrhagic stroke risk of 1.5–2.0% and major bleeding 9.9%. Reserve systemic thrombolysis for truly hemodynamically unstable patients without contraindications.
Intermediate-high risk PE (sPESI ≥1 + RV dysfunction + troponin elevation) represents a clinical dilemma. Catheter-directed thrombolysis (ultrasound-accelerated or standard) delivers drug directly to the clot at lower doses, reducing systemic bleeding risk compared to systemic thrombolysis. PERT activation at centers with this capability is appropriate.
For most PE patients, direct oral anticoagulants (DOACs) are preferred over warfarin. Rivaroxaban and apixaban are approved for PE with no need for parenteral bridging. Rivaroxaban: 15 mg BID for 21 days, then 20 mg daily. Apixaban: 10 mg BID for 7 days, then 5 mg BID. DOACs have equivalent efficacy and lower major bleeding rates compared to warfarin.
In cancer-associated PE, low-molecular-weight heparin (LMWH) has historically been preferred due to unpredictable warfarin absorption in cancer patients. However, DOACs (especially apixaban and rivaroxaban) have shown non-inferior efficacy in the ADAM-VTE, CARAVAGGIO, and SELECT-D trials, with the tradeoff of slightly higher GI bleeding risk in some cancers.
sPESI 0: 30-day all-cause mortality ~1.1% (Jiménez et al. 2010). sPESI ≥1: 30-day all-cause mortality ~8.9%. These benchmarks are from the derivation cohort; real-world values may vary based on population characteristics and institutional PE management practices.
Simplified PESI (sPESI) published by Jiménez et al. (Arch Intern Med 2010). sPESI 0: 30-day mortality 1.1% vs 8.9% for sPESI ≥1. Validated in multiple prospective cohorts. ESC 2019 PE Guidelines (Konstantinides et al.) endorse sPESI as the primary clinical severity tool. sPESI 0 + negative troponin + normal RV permits outpatient treatment consideration per HESTIA and HOME-PE trials. Outpatient PE treatment safety: Aujesky et al. (Lancet 2011 — PESI validation for outpatient).
An sPESI score of 0 identifies a lower-risk group with relatively low 30-day mortality. A score of 1 or more identifies higher-risk patients who generally require inpatient management and closer surveillance.
sPESI supports prognosis and disposition planning, but it does not replace full PE severity assessment, clinician judgment, or evaluation for right-heart strain.
Use sPESI in adults with confirmed acute pulmonary embolism to support early risk stratification and disposition decisions (outpatient pathway versus inpatient monitoring).
It is particularly useful after diagnostic confirmation when planning level of care and discussing short-term prognosis.
sPESI is a binary simplification and can miss nuances captured by broader assessments such as RV dysfunction, biomarkers, clot burden, and dynamic hemodynamics.
A low sPESI score does not by itself guarantee safe outpatient treatment; apply local PE pathway criteria, contraindications to anticoagulation, bleeding risk, and follow-up reliability.
For related assessments, see Wells Score (PE), PERC Rule and Shock Index.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate Wells Score for PE to estimate pretest probability and guide D-dimer testing versus direct CTPA for pulmonary embolism workup.
OpenEmergencyUse PERC (Pulmonary Embolism Rule-out Criteria) to rule out PE in low-risk patients without D-dimer or CT when all 8 criteria are negative.
OpenEmergencyCalculate the Shock Index (HR/SBP ratio) for rapid hemodynamic assessment. Normal: 0.5–0.7. Score ≥1.0 indicates hemodynamic compromise; ≥1.4 indicates severe shock requiring immediate intervention.
OpenEmergencyCalculate qSOFA bedside sepsis risk score. A score of 2 or more (altered mentation, RR ≥22, SBP ≤100) flags high-risk infection requiring urgent evaluation.
Open